thanks  tom

every time you post it, it proves you wrong...by your own hand

odd as it would appear, that must be what you want



ironjustice wrote:

On Jun 13, 3:06 pm, "Paul T. Holland" <pholl... at (no spam) bellatlantic.net
wrote:long winded whack

Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related
Articles, Links
Comment in:
Br J Haematol. 2006 Oct;135(2):271-2.

Effect of enhanced iron chelation therapy on glucose metabolism in
patients with beta-thalassaemia major.

Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos
G,
Tolis G.

Haematological Department, Korinthos General Hospital, Korinthos,
Greece.

Recently introduced chelation regimens that combine deferoxamine
(DFO)
and deferiprone have been shown to have greater efficacy in promoting
iron excretion than either chelator alone and have been associated
with rapid reduction of the iron load in the heart and liver, and
with
reversal of cardiac dysfunction. It is unclear whether this combined
therapy could be associated with a reduction in iron load or decline
in the severity of iron-induced endocrinopathies. Starting in January
2001, 42 patients with beta-thalassaemia major, previously maintained
on subcutaneous DFO only, were switched to combined treatment with
DFO
and deferiprone. The primary endpoint was to investigate the effects
of this therapy on the glucose metabolism characteristics of this
population. Combination therapy markedly decreased ferritin levels
(638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose
responses were improved at all times during an oral glucose tolerance
test, particularly in patients in early stages of glucose
intolerance.
Glucose quantitative secretion also decreased significantly with
combined therapy, while no significant change occurred in insulin
levels in any group. Insulin secretion, according to the homeostasis
assessment model, markedly increased in all groups, while overall
reduction in insulin sensitivity did not reach statistical
significance. This study showed that the combination of DFO and
deferiprone was associated with an improvement in liver iron
deposition and glucose intolerance.

PMID: 16822284 [PubMed - indexed for MEDLINE]

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk- Hide quoted text -

- Show quoted text -

Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related
Articles, Links
Comment in:
Br J Haematol. 2006 Oct;135(2):271-2.

Effect of enhanced iron chelation therapy on glucose metabolism in
patients with beta-thalassaemia major.

Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G,
Tolis G.

Haematological Department, Korinthos General Hospital, Korinthos,
Greece.

Recently introduced chelation regimens that combine deferoxamine (DFO)
and deferiprone have been shown to have greater efficacy in promoting
iron excretion than either chelator alone and have been associated
with rapid reduction of the iron load in the heart and liver, and with
reversal of cardiac dysfunction. It is unclear whether this combined
therapy could be associated with a reduction in iron load or decline
in the severity of iron-induced endocrinopathies. Starting in January
2001, 42 patients with beta-thalassaemia major, previously maintained
on subcutaneous DFO only, were switched to combined treatment with DFO
and deferiprone. The primary endpoint was to investigate the effects
of this therapy on the glucose metabolism characteristics of this
population. Combination therapy markedly decreased ferritin levels
(638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose
responses were improved at all times during an oral glucose tolerance
test, particularly in patients in early stages of glucose intolerance.
Glucose quantitative secretion also decreased significantly with
combined therapy, while no significant change occurred in insulin
levels in any group. Insulin secretion, according to the homeostasis
assessment model, markedly increased in all groups, while overall
reduction in insulin sensitivity did not reach statistical
significance. This study showed that the combination of DFO and
deferiprone was associated with an improvement in liver iron
deposition and glucose intolerance.

PMID: 16822284 [PubMed - indexed for MEDLINE]

Who loves ya.
Tom

Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh

Man Is A Herbivore!http://tinyurl.com/a3cc3

DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk

Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related
Articles, Links
Comment in:
Br J Haematol. 2006 Oct;135(2):271-2.

Effect of enhanced iron chelation therapy on glucose metabolism in
patients with beta-thalassaemia major.

Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G,
Tolis G.

Haematological Department, Korinthos General Hospital, Korinthos,
Greece.

Recently introduced chelation regimens that combine deferoxamine (DFO)
and deferiprone have been shown to have greater efficacy in promoting
iron excretion than either chelator alone and have been associated
with rapid reduction of the iron load in the heart and liver, and with
reversal of cardiac dysfunction. It is unclear whether this combined
therapy could be associated with a reduction in iron load or decline
in the severity of iron-induced endocrinopathies. Starting in January
2001, 42 patients with beta-thalassaemia major, previously maintained
on subcutaneous DFO only, were switched to combined treatment with DFO
and deferiprone. The primary endpoint was to investigate the effects
of this therapy on the glucose metabolism characteristics of this
population. Combination therapy markedly decreased ferritin levels
(638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose
responses were improved at all times during an oral glucose tolerance
test, particularly in patients in early stages of glucose intolerance.
Glucose quantitative secretion also decreased significantly with
combined therapy, while no significant change occurred in insulin
levels in any group. Insulin secretion, according to the homeostasis
assessment model, markedly increased in all groups, while overall
reduction in insulin sensitivity did not reach statistical
significance. This study showed that the combination of DFO and
deferiprone was associated with an improvement in liver iron
deposition and glucose intolerance.

PMID: 16822284 [PubMed - indexed for MEDLINE]

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

cause and effect tommy - out of your own mouth [figuratively speaking of
course]

On Jun 13, 3:06 pm, "Paul T. Holland" <pholl... at (no spam) bellatlantic.net
wrote:long winded whack

Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related
Articles, Links
Comment in:
Br J Haematol. 2006 Oct;135(2):271-2.

Effect of enhanced iron chelation therapy on glucose metabolism in
patients with beta-thalassaemia major.

Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos
G,
Tolis G.

Haematological Department, Korinthos General Hospital, Korinthos,
Greece.

Recently introduced chelation regimens that combine deferoxamine
(DFO)
and deferiprone have been shown to have greater efficacy in promoting
iron excretion than either chelator alone and have been associated
with rapid reduction of the iron load in the heart and liver, and
with
reversal of cardiac dysfunction. It is unclear whether this combined
therapy could be associated with a reduction in iron load or decline
in the severity of iron-induced endocrinopathies. Starting in January
2001, 42 patients with beta-thalassaemia major, previously maintained
on subcutaneous DFO only, were switched to combined treatment with
DFO
and deferiprone. The primary endpoint was to investigate the effects
of this therapy on the glucose metabolism characteristics of this
population. Combination therapy markedly decreased ferritin levels
(638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose
responses were improved at all times during an oral glucose tolerance
test, particularly in patients in early stages of glucose
intolerance.
Glucose quantitative secretion also decreased significantly with
combined therapy, while no significant change occurred in insulin
levels in any group. Insulin secretion, according to the homeostasis
assessment model, markedly increased in all groups, while overall
reduction in insulin sensitivity did not reach statistical
significance. This study showed that the combination of DFO and
deferiprone was associated with an improvement in liver iron
deposition and glucose intolerance.

PMID: 16822284 [PubMed - indexed for MEDLINE]

Who loves ya.
Tom

Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh

Man Is A Herbivore!
http://tinyurl.com/a3cc3

DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk

On Jun 12, 8:55 pm, ironjustice <teamtan... at (no spam) hotmail.com> wrote: Effect
of enhanced iron chelation therapy

"Correlation of serum ferritin concentrations with 2-hour glucose
concentration (top) in 538 nondiabetic persons and insulin
sensitivity
in 257 nondiabetic persons."


http://www.annals.org/cgi/content/full/139/10/869-b?ct


"Bloodletting improved glycemia and insulin sensitivity in patients
with
type 2 diabetes "

from the Annals of Internal Medicine
11/18/03


Association of High Serum Ferritin Concentration with Glucose
Intolerance and
Insulin Resistance in Healthy People


Background:
Increasing evidence points to an association between increased
body iron storage and type 2 diabetes mellitus, even outside the
context of
hemochromatosis (1, 2).
A small intervention study provided preliminary evidence that
bloodletting, which resulted in 50% reduction of serum ferritin
concentrations, improved glycemia and insulin sensitivity in patients
with type 2 diabetes (3).
However, interpretation of mechanistic studies in patients with overt
type 2 diabetes mellitus are complicated because glycemic control
itself influences serum ferritin concentrations (glycosylated ferritin
has a longer serum half-life) and primary effects on insulin
sensitivity or ß-cell function can no longer be studied.
Objective:
To analyze the relationship between iron variables and glucose
tolerance, insulin sensitivity, and ß-cell function in nondiabetic
persons.

Conclusion:
It may become advisable to routinely screen for mildly elevated or
even high-normal serum ferritin concentrations in the context of
glucose
intolerance.
If prospective and interventional studies confirm an etiologic
role of iron overload in the pathogenesis of insulin resistance and
type 2
diabetes, reduced dietary iron intake, especially in men and
postmenopausal
women (9) with additional risk factors for type 2 diabetes, would
appear to be
a logical consequence.
In the future, actively lowering body iron stores may become a tool in
preventing type 2 diabetes in selected subgroups.


Who loves ya.
Tom


Jesus Was A Vegetarian!
http://tinyurl.com/2r2nkh


Man Is A Herbivore!
http://tinyurl.com/a3cc3


DEAD PEOPLE WALKING
http://tinyurl.com/zk9fk




Br J Haematol. 2006 Aug;134(4):438-44. Epub 2006 Jul 4.Related
Articles, Links
Comment in:
Br J Haematol. 2006 Oct;135(2):271-2.

Effect of enhanced iron chelation therapy on glucose metabolism in
patients with beta-thalassaemia major.

Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G,
Tolis G.

Haematological Department, Korinthos General Hospital, Korinthos,
Greece.

Recently introduced chelation regimens that combine deferoxamine (DFO)
and deferiprone have been shown to have greater efficacy in promoting
iron excretion than either chelator alone and have been associated
with rapid reduction of the iron load in the heart and liver, and with
reversal of cardiac dysfunction. It is unclear whether this combined
therapy could be associated with a reduction in iron load or decline
in the severity of iron-induced endocrinopathies. Starting in January
2001, 42 patients with beta-thalassaemia major, previously maintained
on subcutaneous DFO only, were switched to combined treatment with DFO
and deferiprone. The primary endpoint was to investigate the effects
of this therapy on the glucose metabolism characteristics of this
population. Combination therapy markedly decreased ferritin levels
(638 +/- 1345 vs. 2991 +/- 2093 microg/l, P < 0.001). Glucose
responses were improved at all times during an oral glucose tolerance
test, particularly in patients in early stages of glucose intolerance.
Glucose quantitative secretion also decreased significantly with
combined therapy, while no significant change occurred in insulin
levels in any group. Insulin secretion, according to the homeostasis
assessment model, markedly increased in all groups, while overall
reduction in insulin sensitivity did not reach statistical
significance. This study showed that the combination of DFO and
deferiprone was associated with an improvement in liver iron
deposition and glucose intolerance.

PMID: 16822284 [PubMed - indexed for MEDLINE]

Who loves ya.
Tom

Jesus Was A Vegetarian!http://tinyurl.com/2r2nkh

Man Is A Herbivore!http://tinyurl.com/a3cc3

DEAD PEOPLE WALKINGhttp://tinyurl.com/zk9fk

On Jun 13, 6:00 pm, "Paul T. Holland" <pholl... at (no spam) bellatlantic.net
wrote:long winded whack

You can't seem to get the .. drift .. man ..

YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!

Stay off my threads ..


Who loves ya.
Tom

...... stop posting this out of date crap.

On Fri, 13 Jun 2008 20:34:11 -0500, ironjustice wrote
(in article
93bc6985-7e40-4cb6-a65a-93b20826504a at (no spam) 26g2000hsk.googlegroups.com>):

On Jun 13, 6:00 pm, "Paul T. Holland" <pholl... at (no spam) bellatlantic.net
wrote:long winded whack

You can't seem to get the .. drift .. man ..

YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!
YOU ARE A FKG WHACKJOB .. !!

Stay off my threads ..


Who loves ya.
Tom


Your true color (rust) finally comes out.